ZA200301312B - Peptide structures useful for competitive modulation of dipertidyl peptidase IV catalysis. - Google Patents

Peptide structures useful for competitive modulation of dipertidyl peptidase IV catalysis. Download PDF

Info

Publication number
ZA200301312B
ZA200301312B ZA200301312A ZA200301312A ZA200301312B ZA 200301312 B ZA200301312 B ZA 200301312B ZA 200301312 A ZA200301312 A ZA 200301312A ZA 200301312 A ZA200301312 A ZA 200301312A ZA 200301312 B ZA200301312 B ZA 200301312B
Authority
ZA
South Africa
Prior art keywords
acid
pro
amino acid
compound
gly
Prior art date
Application number
ZA200301312A
Inventor
Hans-Ulrich Demuth
Torsten Hoffmann
Susanne Manhart
Matthias Hoffmann
Jochen Heins
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of ZA200301312B publication Critical patent/ZA200301312B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Peptide Structures Useful for Competitive Modulation of Dipeptidyl Peptidase IV
Catalysis
BACKGROUND OF THE INVENTION Field of the invention
The present invention relates to the function of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5) and DP IV-like enzymes within a subject and their biological effects on the plasma levels of the insulinotropic peptides gastric inhibitory polypeptide 1-42 (GIP) and glucagon-like peptide amides-1 (GLP-17.36) + and (GLP-1,47) or analogues thereof. The invention relates further to the treatment of impaired glucose tolerance, diabetes mellitus, glucosuria and metabolic acidosis by selective modulation of the activity of DP IV-like enzymes due to the use of tri-, tetra- and pentapeptide substrates of dipeptidyl peptidase IV in pharmacological doses to inhibit the physiological turnover of endogenous peptide hormones.
Background of the invention
Dipeptidy! peptidase IV (DP IV) is a serine protease which cleaves off N-terminal dipeptides from a peptide chain containing, preferably a proline residue in the penultimate position.
DP IV-like enzymes are structurally related enzymes to DP IV (Blanco et. al., 1998) which may share a certain sequence homology to the DP IV sequence, but which share even if they are not structurally related (by convergent evolution) the substrate specificity of DP IV of removing dipeptides from the N-termini of polypeptides by cleaving after a penultimate proline residue. Such enzymes — including DP IV, DP Il at one hand and attractin on the other hand (Fukasawa et al., 2001) — are also capable to remove dipeptides with a penultimate alanine (or serine or glycine residues) from the N-termini of polypeptides but usually with reduced catalytic efficacy as compared to the post-proline cleavage (Yaron & Naider, 1993). They show the common feature that they accommodate in the Pro-position of the target-protein also Ala, Ser, Thr and other amino acids with small hydrophobic side-chains as, Gly or Val. The hydrolytic
C2
X efficacy is ranked Pro>Ala» Ser, Thr » Gly, Val. While the proteins DPIV, DP II, FAPx (Seprase), DP 6, DP 8 and DP 9 are structurally related and show a high sequence . homology, attractin is an extraordinary functional DPIV-like enzyme (Sedo & Malik, 2001). :
Further DPIV-like enzymes are disclosed in WO 01/19866, WO 02/04610, WO 02/34900 and WOO02/31134. WO 01/19866 discloses human dipeptidyl aminopeptidase 8 (DPP8) with structural und functional similarities to DPIV and fibroblast activation protein (FAP). The dipeptidy! peptidase IV-ike enzyme of WO 02/04610 is well known in the art. In the GENE BANK data base, this enzyme is registered as KIAA1492 (registration in February 2001, submitted on April 04, 2000,
ABD40925) and in the MEROPS data base. WO 02/34900 discloses a dipeptidyl peptidase 9 (DPP9) with significant homology to the amino acid sequences of DPIV and DPP8. WO 02/31134 discloses three DPIV-like enzymes, DPRP1, DPRP2 and
DPRP3. Sequence analysis revealed that DPRP1 is identical to DPP8, as disclosed in
WO 01/19866, that DPRP2 is identical to DPP9 and that DPRP3 is identical to
KIAA1492 as disclosed in WO 02/04610.
More recently, it was shown that DP IV is responsible for cleaving glucagon-like peptide-1 and gastric inhibitory peptides, thereby shortening the half life of GLP-1 and
GIP and their physiological response in the circulation. From inhibition of serum DP
IV, a significant increase in the bioactivity of the incretins has been shown. Since the incretins are major stimulators of pancreatic insulin secretion and have direct beneficial effects on glucose disposal, DP IV inhibition represents an attractive approach for treating impaired glucose tolerance and non-insulin-dependent diabetes mellitus (NIDDM) and related disorders, like glucosuria and metabolic acidosis (see ’ DE 196 16 486 and WO 97/40832).
The substrate specificity of the enzyme dipeptidy! peptidase IV, may be summarized in the following way: 1. Dipeptidyl peptidase IV hydrolyzes oligopeptides and proteins from the N- terminus, splitting off dipeptide units, when the penuitimate residue is proline,
} hydroxyproline, dehydroproline, pipecolic acid or alanine. The best substrates according to their k.s/Km values are those with a proline residue in the P1- . position. 2. DP IV requires a trans’ peptide-bond between P1 and P2 residues. 3. The N-terminal amino group of substrates must be protonated in order to be susceptible to DP IV. 4. A proline residue in the P1’-position of substrates prevents substrate hydrolysis by dipeptidyl peptidase IV. This enzyme does not release arginylproline from bradykinin, for instance.
Summary of the invention
The present invention is directed to compounds represented by formula (1), pd Ba rd Pe
A c E with certain restrictions as detailed hereafter.
These compounds are substrates of proline-specific peptidases, in particular of DP IV and other enzymes having similar DP IV-like enzymatic activity profiles (‘DP IV-like enzymes”), and may be useful either as substrates or as antagonists of DP IV and DP
IV-like enzymes to inhibit the physiological tumover of endogenous peptide hormones by competitive catalysis.
The compounds of formula (I) may be used for treating impaired glucose tolerance, . diabetes mellitus, glucosuria, metabolic acidosis diagnosed in a subject, cancer and multiple sclerosis.
Brief description of the drawings ] Figure 1 shows plasma DP IV activity after intravasal administration of 10, 30 and 100 mg/kg b.w. lle-Pro-lie in Wistar rats;
Figure 2 shows plasma DP IV activity after administration of 10, 30 and 100 mg/kg b.w. lle-Pro-lle and of 10 mg/kg b.w. and isoleucy! thiazolidine fumarate as positive control in Wistar rats (AUC 0-20 min);
Figure 3 shows plasma DP IV activity after intravasal administration of 10, 30 and 100 mg/kg b.w. Val-Pro-Leu in Wistar rats;
Figure 4 shows plasma DP IV activity after administration of 10, 30 and 100 mg/kg b.w. Val-Pro-Leu and of 10 mg/kg b.w. isoleucyl thiazolidine fumarate as positive control in Wistar rats (AUC 0-20 min);
Figure 5 shows plasma DP IV activity after oral and intravasal administration of 100 mg/kg b.w. f-butyl-Gly-Pro-lle in Wistar rats;
Figure 6 shows plasma DP IV activity after oral and intravasal administration of 100 mg/kg b.w. t-butyl-Gly-Pro-lle, and of 10 mg/kg b.w. isoleucyl thiazolidine fumarate as positive control in Wistar rats(AUC 0-120 min);
Figure 7 shows the course of plasma glucose concentration after oral administration ’ of 100 mg/kg b.w. t-butyi-Gly-Pro-lle, and of 10 mg/kg b.w. isoleucyl thiazolidine fumarate as positive control in diabetic Zucker rats; and
Figure 8 shows the improvement of glucose tolerance and G-AUC during OGTT after oral administration of 100 mg/kg b.w. f-butyl-Gly-Pro-lle, and of 10 mg/kg b.w.
. isoleucyl thiazolidine fumarate as positive control diabetic Zucker rats (G-AUC 0-60 min). oo
Detailed description of the invention
More particularly, the present invention is directed to peptides of the following formula (1):
B D
Az No Ng (I) wherein
A, B, C, D and E are any amino acids including proteinogenic amino acids, non- proteinogenic amino acids, L-amino acids and D-amino acids and wherein E and/or
D may be absent or B and/or A may be absent with additional conditions as hereinafter detailed:
Further conditions regarding formula (1):
A is any amino acid residue except a D-amino acid;
B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid,
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,, } D is any amino acid or missing, and
E is any amino acid or missing or
. C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a
D- amino acid,
D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and
E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine..
The present invention especially refers to compounds of formula (I) wherein
A is any amino acid except a D-amino acid;
B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid,
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,,
D is any amino acid or missing, and
E is any amino acid or missing.
The present invention moreover refers to compounds of formula (I) wherein
A is any amino acid except a D-amino acid; ' B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid,
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a
D- amino acid,
. D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine~(2)-carboxylic acid and pipecolic acid, and ‘ E is any amino acid except from Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine.
Preferred
Ais a L-amino acid.
Further preferred
C is a L-amino acid; further preferred
E is a missing; further preferred
D and E are missing; further preferred
Ais t-butyl-Gly, lle or Val, especially preferred
A is t-butyl-Gly; further preferred
B is Pro; further preferred
D is Pro; further preferred
C is t-butyl-Gly, lle or Val;
+ v 8 } more preferred
C is t-butyl-Gly or Val; especially preferred
C is t-butyl-Gly; especially preferred are t-butyl-Gly-Pro-lie; t-butyl-Gly-Pro-Val; Val-Pro-t-butyl-Gly, lle-Pro-t-butyl-Gly or f- butyl-Gly-Pro-t-butyl-Gly and pharmaceutically acceptable salts thereof.
The compound of the present invention can be in the free acid peptide form or the C- terminal amide peptide form.
The compounds of the present invention may be present as the free C-terminal acid or as the C-terminal amide form. The free acid peptides or the amides may be varied by side chain modifications. Such side chain modifications are for instance, but not restricted io, homoserine addition, pyroglutamic acid addition, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t-butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, benzyloxymethylation, 4-nitrophenylation, benzyloxycarbonylation, 2- nitrobencoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2-chlorobenzyloxycarbonylation, 2,4,5- trichlorophenylation, 2-bromobenzyloxycarbonylation, 9- fluorenylmethyloxycarbonylation, triphenyimethylation, 2,25,7.8,- pentamethylchroman-6-sulphonylation, hydroxylation, oxidation of methionine, ' formylation, acetylation, anisylation, benzylation, benzoylation, trifluoroacetylation, carboxylation of aspartic acid or glutamic acid, phosphorylation, sulphation, cysteinylation, glycolysation with pentoses, deoxyhexoses, hexosamines, hexoses or
N-acetylhexosamines, farnesylation, myristolysation, biotinylation, palmitoylation, stearoylation, geranylgeranylation, glutathionylation, &-adenosylation, ADP-
ribosylation, modification with N-glycolylneuraminic acid, N-acetylneuraminic acid, pyridoxal phosphate, lipoic acid, 4'-phosphopantetheine, or N-hydroxysuccinimide.
In the compounds of formula (1), the amino acids A, B, C, D, and E, respectively, are attached to the adjacent amino acid with amide bonds in a usual manner and according to standard nomenclature so that the amino-terminus (N-terminus) of the amino acids is drawn on the left and the carboxyl-terminus of the amine acid is drawn on the right.
Examples of amino acids which can be used in the present invention are
L and D-amino acids, N-methyl-amino-acids; allo- and threo-forms of lle and Thr, which can, e.g. be a-, B- or ®-amino acids, whereof a-amino acids are preferred.
Examples of amino acids are: aspartic acid (Asp), glutamic acid (Glu), arginine (Arg), lysine (Lys), histidine (His), glycine (Gly), serine (Ser) and cysteine (Cys), threonine (Thr), asparagine (Asn), glutamine (GIn), tyrosine (Tyr), alanine (Ala), proline (Pro), valine (Val), isoleucine (lle), leucine (Leu), methionine (Met), phenylalanine (Phe), tryptophan (Trp), hydroxyproline (Hyp), beta-alanine (beta-Ala), 2-amino octanoic acid (Aoa), azetidine- (2)-carboxylic acid (Ace), pipecolic acid (Pip), 3-amino propionic, 4-amino butyric and so forth, alpha-aminoisobutyric acid (Aib), sarcosine (Sar), ornithine (Om), citrulline (Cit), homoarginine (Har), t-butylalanine (t-butyl-Ala), t-butylglycine (f-butyl-Gly), N- methylisoleucine (N-Melle), phenylglycine (Phg), cyclohexylalanine (Cha), norleucine (Nle), cysteic acid (Cya) and methionine sulfoxide (MSO), Acetyl-Lys, modified amino acids such as phosphoryl-serine (Ser(P)), benzyl-serine (Ser(Bzl)) and phosphoryl- tyrosine (Tyr(P)), 2-aminobutyric acid (Abu), aminoethylcysteine (AECys), carboxymethylcysteine (Cmc), dehydroalanine (Dha), dehydroamino-2-butyric acid (Dhb), carboxyglutaminic acid (Gla), homoserine (Hse), hydroxylysine (Hyl), cis- hydroxyproline (cisHyp), trans-hydroxyproline (transHyp), isovaline (Iva), pyroglutamic acid (Pyr), norvaline (Nva), 2-aminobenzoic acid (2-Abz), 3- aminobenzoic acid (3-
Abz), 4- aminobenzoic acid (4-Abz), 4-(aminomethyl)benzoic acid (Amb), 4-
(aminomethyl)cyclohexanecarboxylic acid (4-Amc), Penicillamine (Pen), 2-Amino-4- cyanobutyric acid (Cba), cycloalkane-carboxylic aicds. : Examples of w-amino acids are e.g.: 5-Ara (aminoraleric acid), 6-Ahx (aminohexanoic acid), 8-Aoc (aminooctancic aicd), 9-Anc (aminovanoic aicd), 10-Adc (aminodecanoic acid), 11-Aun (aminoundecanoic acid), 12-Ado (aminododecanoic acid).
Further amino acids are: indanylglycine (lgl), indoline-2-carboxylic acid (ide), octahydroindole-2-carboxylic acid (Oic), diaminopropionic acid (Dpr), diaminobutyric acid (Dbu), naphtylalanine (1-Nal), (2-Nal), 4-aminophenylalanin (Phe(4-NHyp)), 4- benzoylphenylalanine (Bpa), diphenylalanine (Dip), 4-bromophenylalanine (Phe(4-
Br)), 2-chlorophenylalanine (Phe(2-Cl)), 3-chlorophenylalanine (Phe(3-Cl)), 4- chlorophenylalanine (Phe(4-Cl)), 3,4-chlorophenylalanine (Phe (3,4-Cly)), 3- fluorophenylalanine (Phe(3-F)), 4- fluorophenylalanine (Phe(4-F)), 3,4- fluorophenylalanine ~~ (Phe(3,4-F,)), pentafluorophenylalanine (Phe(Fs)), 4- guanidinophenylalanine (Phe(4-guanidino)), homophenylalanine (hPhe), 3- jodophenylalanine (Phe(3-J)), 4 jodophenylalanine (Phe(4-J)), 4-methylphenylalanine (Phe(4-Me)), 4-nitrophenylalanine (Phe-4-NO,)), biphenylalanine (Bip), 4- phosphonomehtylphenylalanine (Pmp), cyclohexyglycine (Ghg), 3-pyridinylalanine (3-
Pal), 4-pyridinylalanine (4-Pal), 3,4-dehydroproline (A-Pro), 4-ketoproline (Pro(4- keto)), thioproline (Thz), isonipecotic acid (inp), 1,2,3,4,-tetrahydroisoquinalin-3- carboxylic acid (Tic), propargylglycine (Pra), 6-hydroxynorleucine (NU(8-OH)), homotyrosine (hTyr), 3-jodotyrosine (Tyr(3-J)), 3,5-dijodotyrosine (Tyr(3,5-J2)), d- . methyl-tyrosine ~~ (Tyr(Me)), 3-NOz-tyrosine (Tyr(3-NOy)), phosphotyrosine (Tyr(POsH2)), alkylglycine, 1-aminoindane-1-carboxy acid, 2-aminoindane-2-carboxy acid (Aic), 4-amino-methylpyrrol-2-carboxylic acid (Py), 4-amino-pyrrolidine—2- carboxylic acid (Abpc), 2-aminotetraline-2-carboxylic acid (Atc), diaminoacetic acid (Gly(NHy)), diaminobutyric acid (Dab), 1,3-dihydro-2H-isoinole-carboxylic acid (Disc), homocylcohexylalanin (hCha), homophenylalanin (hPhe oder Hof), trans-3-phenyl- azetidine-2-carboxylic acid, 4-phenyl-pyrrolidine-2-carboxylic acid, 5-phenyl- pyrrolidine-2-carboxylic acid, 3-pyridylalanine (3-Pya), 4-pyridylalanine (4-Pya), styrylalanine, tetrahydroisoquinoline-1-carboxylic acid (Tig), 1,2,3,4- tetrahydronorharmane-3-carboxylic acid (Tpi), 3-(2-thienryl)-alanine (Tha)
Other amino acid substitutions for those encoded in the genetic code can also be included in peptide compounds within the scope of the invention.
The present invention furthermore refers to a pharmaceutical composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier and/or diluent.
Such pharmaceutical compositions can be prepared by mixing at least one compound of the present invention and a pharmaceutically acceptable carrier and/or diluent.
The compounds and compositions according to the present invention can be used for the preparation of a medicament for the prophylaxis or treatment of a condition mediated by modulation of the dipeptidyl peptidase IV activity.
Such conditions are, e.g. selected from impaired glucose tolerance, diabetes mellitus, glucosuria, metabolic acidosis, cancer and multiple sclerosis.
The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
As used herein, the term “composition” is intended to encompass a product comprising at least one of the compounds of the present invention in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
The compounds of the present invention may also be present in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt generally takes a form in which an amino acids basic side chain is protonated with an inorganic or organic acid. Representative organic or inorganic acids include, e.g. hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesuifonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p- toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid.
The present invention further includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound. Thus, in these cases, the use of the present invention shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of
Prodrugs”, ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 1388 28 113; WO 99/67278, DE 198 28 114 and WO 99/67279, fully incorporated herein by reference.
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention.
In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
Until the present invention by Applicants, known peptide substrates of the proline- specific serine protease dipeptidyl peptidase IV in vitro are the tripeptides Diprotin A : (lle-Pro-lle), Diprotin B (Val-Pro-Leu) and Diprotin C (Val-Pro-lle). These compounds per se are excluded from the present invention. Applicants have unexpectedly discovered that the compounds disclosed here act as substrates of dipeptidyl peptidase IV in vivo and, in pharmacological doses, inhibit the physiological turnover of endogenous peptide hormones by competitive catalysis.
Particularly preferred compounds or prodrugs of the present invention that could be useful as modulators of dipeptidy! peptidase IV and DP IV — like enzymes include those compounds or prodrugs which show K-values for DP IV binding, effectivity in
DP IV inhibition in vivo after intravasal (i.v.) and/or oral (p.o.) administration to Wistar rats and improved glucose tolerance in vivo after i.v. and p.o. administration to falfa
Zucker rats.
The modulators of this invention may be prepared using solid phase chemistry or, alternatively, via normal solution chemistry, using conventional methods known in the art.
The utility of the compounds of formula (I) to act as DP IV substrates to inhibit the physiological turnover of endogenous peptide hormones by competitive catalysis in vivo can be determined according to the procedures described in Examples 3 and 4.
The present invention therefore provides a method of preventing or treating a condition mediated by modulation of the DP IV activity in a subject in need thereof which comprises administering any of the compounds or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition. Additionally, the present invention includes the use of a compound of formula (I) for the preparation of a medicament for the prevention or treatment of a condition mediated by modulation of the DP IV activity in a subject. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral or combinations thereof. Oral administration is preferred.
Co . 1
The present invention also provides pharmaceutical compositions comprising one or oo more compounds of this invention in association with a pharmaceutically acceptable carrier and/or diluent.
To prepare the pharmaceutical compositions of this invention, one or more compounds of formula (I) or salts thereof as the active ingredients, are intimately admixed with a pharmaceutical carrier and/or diluent according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 mg to about 1000 mg (preferably about 5 to about 500 mg) and may be given at a dosage of from about 0.1 to about 300 mg/ kg bodyweight per day (preferably 1 to 50 mg/kg per day). The dosages, however, may be varied depending upon the requirement of the patients, : the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed. Typically the dosage will be regulated by the physician based on the characteristics of the patient, his/her condition and the therapeutic effect desired.
Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is ideally mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is ideally dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
This solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.01 to about 1000 mg, preferably from about 5 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the novel composition can be advantageously coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be advantageously incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylceliulose, methylcellulose, polyvinylpyrrolidone or gelatin.
Where the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoy-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic
Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M.
Wuts, Protective Groups in Organic_Synthesis, John Wiley & Sons, 1991, fully : incorporated herein by reference. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
The method of treating conditions modulated by dipetidyl peptidase IV and DP IV - like enzymes described in the present invention may also be carried out using a pharmaceutical composition comprising one or more of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.01 mg and 1000 mg, preferably about 5 to about 500 or 250 mg of the compounds, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen and dosage strength will need to be accordingly modified to obtain the desired therapeutic effects.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmacedutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can : also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
The liquid forms in suitable flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired.
Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines using processes well described in the art.
Compounds of the present invention may also be delivered by the use of antibodies, most preferably monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenoal, polyhydroxyethylaspartamidephenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross- linked or amphipathic block copolymers of hydrogels.
Compounds of this invention may be administered in any of the foregoing . compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
The daily dosage of the products may be varied over a wide range from 0.01 to 1.000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250, 500 and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day. Preferably, the range is from about 1 to about 50 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, bioavailability due to the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, should generally be considered in adjusting dosages.
The compounds or compositions of the present invention may be taken before a meal, while taking a meal or after a meal.
When taken before a meal, the compounds or compositions of the present invention can be taken 1 hour, preferably 30 or even 15 or 5 minutes before eating.
When taken while eating, the compounds or compositions of the present invention can be mixed into the meal or taken in a separate dosage form as described above.
When taken after a meal, the compounds and compositions of the present invention can be taken 5, 15, or 30 minutes or even 1 hour after finishing a meal.
EXAMPLES OF THE INVENTION
Example 1
Synthesis of Xaa-Pro-Yaa tripeptides
General procedure
All syntheses were carried out on a peptide synthesizer SP 650 (Labortec AG) applying Fmoc/tBu-strategy. Protected amino acids were purchased from
Novabiochem or Bachem. Trifluoro acetic acid (TFA) was purchased from Merck, triisopropyl silane (TIS) was purchased from Fluka.
Pre-loaded Fmoc-Yaa-Wang resin (2.8 g/ substitution level 0.57 mmol/g) was deprotected using 20% piperidine/ N,N-dimethylformamide (DMF). After washing with
DMF a solution of 2 eq (1.1 g) of Fmoc-Pro-OH were solved in DMF (12mi solvent per gram resin). 2eq (1.04 g) of 2-(1 H-Benzotriazole 1-yi)-1,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 4 eq (1.11mi) of N,N-diisopropylethylamine (DIEA) were added and placed in the reaction vessel. The mixture was shaken at room temperature for 20 minutes. Then, the coupling cycle was repeated. After subsequent washing with DMF, dichlormethane, isopropanol and diethyl ether the resulting Fmoc-
Pro-lle-Wang resin was dried and divided into 6 parts before coupling the last amino acid derivative.
Fmoc protecting group was removed as described above. After that 0.54 mmol of the
Boc-amino acid, 0.54 mmol TBTU and 0.108 mmol DIEA in DMF were shaken for 20 min. The coupling cycle was repeated. Finally the peptide resin was washed and dried described above.
The peptide was cleaved from the resin using a mixture of trifluoroacetic acid (TFA) for 2.5 h, containing the following scavengers: TFA/H,O/triisipropylsilane (TIS) = : 9.5/0.25/0.25
The yields of crude peptides were 80-90% on the average. The crude peptides were purified by HPLC on a Nucleosil C18 column (7 um, 250*21.20 mm, 100 A) using a linear gradient of 0.1% TFA/H,O with increasing concentration of 0.1%
TFA/acetonitrile (from 5% to 65% in 40 min) at 6 ml/min.
The pure peptides were obtained by lyophilization, identified by Electrospray mass spectrometry and HPLC analysis.
Results
Table 1: Identification of Xaa-Pro-Yaa tripeptides after chemical synthesis
Peptide Mass (exp.) HPLC k‘ [M+H"] 2-Amino octanoic acid- 369.5 370.2 10.63
Pro-lle
Abu-Pro-lle 313.4 314.0
Aib-Pro-lie 313.4 314.0
Aze-Pro-lle 311.4 312.4
Cha-Pro-lle 381.52 382.0 lle-Hyp-lle 356.45 358.2 lle-Pro-allo-lle 341.4 342.0 lle-Pro-t-butyl-Gly 341,47 342,36 lle-Pro-Val 327.43 328.5
Nie-Pro-lie 341.45 342.2
FRCP Gy] SAE | SEs | Sm '[M+H"] were determined by Electrospray mass spectrometry in positive ionization mode. 2 RP-HPLC conditions: . column: LiChrospher 100 RP 18 (5um), 125 x4 mm detection (UV): 214nm gradient system: acetonitrile (ACN)/H.0 (0.1% TFA) from 5% ACN to 50% in15 min,
flow 1 ml/min : K' = (t-to)/to to = 1.16 min t-butyl-Gly is defined as:
KN ats
Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively.
Tyr(P) is defined as phosphoryi-tyrosine.
Example 2
Determination of ICso- and K;-values of Xaa-Pro-Yaa tripeptides
Methods
Determination of ICs,-values 100 HI inhibitor stock solution were mixed with 100 pi buffer (HEPES pH 7.6) and 50 pl substrate (Gly-Pro-pNA, final concentration 0.4 mM) and preincubated at 30°C.
Reaction was started by addition of 20 pl purified porcine DP IV. Formation of the product pNA was measured at 405 nm over 10 min using the HTS 7000Plus plate reader (Perkin Elmer) and slopes were calculated. The final inhibitor concentrations - ranged between 1 mM and 30 nM.
For calculation of ICso-values GraFit 4.0.13 (Erithacus Software) was used.
. Determination of K; -values
For determination of the K-values DP IV activity was measured in the same way as : described above at final substrate concentrations of 0.05, 0.1, 0.2, and 0.4 mM and further 7 inhibitor concentrations covering the ICso concentration. Calculations were performed using the GraFit Software.
Results
Table 2: ICso-values of Xaa-Pro-Yaa tripeptides i Jc peels | soo t-butyl-Gly-Pro-Gly 5.63e-5 1.67e-6 t-butyl-Gly-Pro-lle 9.34e-6 9.08e-7 . | t-butwt-Gly-Pro-fie-NH. 2.29e-5 1.13e-6 t-butyl-Gly-Pro- t-butyl-Gly 2.45e-5 8.01e-7 t-butyl-Gly-Pro-Val 1.38e-5 1.28e-6
Thr-Pro-lie 1.00e-4 4.43e-6
Tic-Pro-lle 0.0008 9.28e-6
Trp~Pro-lle 3.17e-4 1.80e-5
Tyr(P)-Pro-lle 1.77e-3 9.36e-4
Tyr-Pro-(allo)lle 6.41e-5 3.07e-6
Val-Pro-(allo)lle 7.61e-7
Val-Pro-Val 1.64e-5 1.22e-6 t-butyl-Gly is defined as:
ENG aad
Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively.
Tyr(P) is defined as phosphoryl-tyrosine.
Table 3: K; -values of Xaa-Pro-Yaa tripeptides
Kah bi
Abu-Pro-lie 8.75e-6 1.52e-6
Aze-Pro-lle 2.05e-5 3.77e-6
Cha-Pro-lle 5.99e-6 2.11e-7
Diprotin A 3.45e-6 2.08e-7 t-butyl-Gly is defined as:
ENG
: Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively.
Tyr(P) is defined as phosphoryl-tyrosine.
EXAMPLE 3
The influence of Xaa-Pro-Yaa tripeptides on plasma activity of DP IV after intravasal and oral administration in Wistar rats
STUDY DESIGN
ANIMALS
N=10 male Wistar rats (Shoe:Wist(Sho)) with a body weight >350 g were purchased from Tierzucht Schénwalde (Schénwalde, Germany).
HousING CONDITIONS
Animals were single-housed under conventional conditions with controlled temperature (22+2 °C) on a 12/12 hours light/dark cycle (light on at 06:00 AM).
Standard pelleted chow (ssniff® Soest, Germany) and tap water acidified with HCI were allowed ad libitum.
CATHETERIZATION OF CAROTID ARTERY AND JUGULAR VEIN
After one week of adaptation to housing conditions, catheters were implanted into the carotid artery of Wistar rats under general anaesthesia (i.p. injection of 0.25 ml/kg b.w. Rompun® [2 %], BayerVital, Germany and 0.5 ml/kg b.w. Ketamin 10, Atarost
GmbH & Co., Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 IU/ml) three times per week.
In case of catheter dysfunction, a second catheter was inserted into the contralateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 5 days after catheter implantation.
EXPERIMENTAL DESIGN
. Rats with intact catheter function were given the test substances intravasal (intraarterial) or oral, respectively, in random order (N=3 Wistar rats in each group). -
As positive control, 10 mg/kg b.w. isoleucine thiazolidine*fumarate were administered intravasal.
After overnight fasting, 100 pl samples of heparinized arterial blood were collected at -30, -5, and 0 min into ice-cooled Eppendorf tubes (see below). The test substances were dissolved freshly in 1.0 ml saline (0.154 mol/l) and were given at 0 min either oral via a feeding tube (15g, 75 mm; Fine Science Tools, Heidelberg, Germany) or intravasal. For the intravasal route, the catheter was immediately flushed with 30 il saline and an additional 1 mi of saline was given orally via the feeding tube.
Arterial blood samples were taken thereafter at 5, 10 (only in a limited number of experiments), 20, 40, 60 and 120 min from the carotid catheter of the conscious unrestrained rats and were always given into ice cooled Eppendorf tubes (Eppendorf-
Netheler-Hinz, Hamburg, Germany) filled with 10 pi 1 M citrate buffer pH 3.0 for prevention of further hydrolysis of tripeptides by plasma DP IV activity. Eppendorf tubes were centrifuged immediately (12000 rpm for 2 min, Hettich Zentrifuge EBA 12,
Tuttlingen; Germany): The plasma fractions were store on ice until analysis ar were deeply frozen at —20 °C until analysis.
ANALYTICAL METHODS
Plasma DP IV activity: The assay mixture consisted of 80 pl reagent and 20 ul plasma. Kinetic measurements of the formation of the yellow product 4-nitroaniline were performed at 390 nm for 1 min at 30 °C after 2 min pre-incubation at the same temperature. The activity was expressed as arbitrary units [AU] and DP IV activity [mU/mi].
STATISTICAL METHODS
The absolute values of plasma DP IV activity, the relative change of plasma DP IV : activity and the time and extent of maximal inhibition were calculated. Data presentation included the presentation of area under the curve (AUC), which was used for evaluation of extent of inhibition of plasma DP IV activity during the two hours of observation. AUC was calculated using the trapezoidal rule. Reactive AUC had a baseline with the value at 0 min with beginning of the inhibitor administration.
To compare relative changes of parameters under the conditions of different initial values of DP IV activity an uniform standardised mean (values) was set up at the beginning of the test (see Figures and Tables).
Statistical evaluations were performed with Microsoft Excel® 97. All variables are presented as mean and standard deviation (SD). Treatment groups were compared by Student's t-test, within-group changes by paired t-test. Two-tailed values of p<0.05 were considered significant.
Results
THE INFLUENCE OF ILE-PRO-ILE ON PLASMA DP IV AcTIVITY IN WISTAR-RATS
Ascending doses of lle-Pro-lle of 10, 30 and 100 mg/kg b.w. were administered to
Wistar rats via intravasal route (Table 1).
After intravasal administration of lle-Pro-lle there is a tendency of dose-dependent plasma DP IV inhibition by lle-Pro-lle. This inhibition was significant only at the dose of 100 mg/kg b.w. (with respect to DP IV activity at time 0 min). See Figure 1 which shows that the inhibition of DP IV by lle-Pro-lle was decreased rapidly. 20 minutes after administration, the initial level of dipeptidy! peptidase IV activity was restored.
With reference to Figure 2, it can be seen that the area under the curve of DP IV activity at the dose of 100 mg/kg b.w. was significantly decreased (-159 +40 mU*min*ml™!, p<0.05).
a
FI ed ce E ol ola FI A Ee © Sg af wn Q y Ola: gy
CER EE ERSRBES Ss gegg
E © Fi Ee| — fi 2 Ov «~ «
Eo|E a iEa Eot3 GE E of Ri ~ : 00: « Se | 00:
OYNETINISS CNSR BAY oc NB BES
S&T “TE Dal NTEEe SAN mie x) fF < IY i a FUR 0 Siw mb oy os fio gle & @imin 4
BS Blai oF Ss + Blo of wits « Ble © ofl oF o a Fi al EA ale vp *
A. « E o . E ib « E (1) © 2 lee) oc 2 oo °c 2 aio
Fs - £5 . £2 = g E i E HE E Eo 8S Zenit go Zetni@on Zl fii = =m mm oly — 0: a Els oli eo * 8 ER QR Elle 2k Ew = woo
S = & = : = .
Q; Ho He iH © 384 fe Hh — ole NOD © 0 olN © oN — ole © offi on © NaF 7 Of 7 ON Nis 15 SE og Sle oS Wioiey 5 @ 0 oN; i 2 olrwalgoo olemnfgos ols noida, = 0 OF oi] > 0 | — Wo o ola efiin x oltoelEvn ono wlEv ow Sf NY Oo wi oN J |g 2 EI i: TRIS CR JISNIETAE © NN old no ow <li o ~w wl|gioon 2) Qin gleoy Ql cg wlin or © Rie of Flair rs ERR] Nig Qe NE N= © = pi i fit fa i Fre © 0 wv Cid N o BH o Fiois Of r= lh a [+] ~~ $i -— HEH —(® 0 ON: ° ~~ AH (iid Sh «= 17] i i ail == iit Rit Jie = oS NEL OO oloE Sen ee MTom — 3 oF of o fo 0 Figo « © 5 SRN] gwen w Feo > olRami= =o Mw 2d — o - = aldguo 3 0 © EE o 0 J oo IY Ole v= «F|oiien 110 > ERR S/2E”A SSIIEOR = Bi iid HH < oleeniE aa olee=foo ole amon
NO DIRE DWN MO {10:00 CO [1 om ~ EGE a RIFE eRI\{UI = Hi ii i a. W le amido w leo afta Ww iso xigin o =8Snalnsy =89Sesiing =Z9dcsEoy
Q ENA et Fi PICS EREIREC © Fee] 2% hens HH : Sins a N © o © i= Alesis SERN 85 EB 5
Q is <<< Ole < Ole << = ES =a = = 83 = = mS = =
Se . Tk : Red o ed I] fon a Ee © 2 Bexar £ ExaelIl ET Exod 0B rel Wolo oon Ne Solo ow 8 Holo oo 8 o Haan ww 0 EOC wow @ ofa) [ngage 2 -
THE INFLUENCE OF VAL-PRO-LEU ON PLASMA DP IV ACTIVITY IN WISTAR-RATS : A tendency to decline plasma DP IV activity was seen after 10 and 30 mg/kg b.w. of
Val-Pro-Leu given intravasal (Figure 3). After 10 mg/kg b.w. lowest plasma activity was 26.2+8.0 mU/ml at 5 min (NS) and after 30 mg/kg it was 21.849.8 (NS). This was alsa reflected in the low DP [V-AUCo.20 min Of -34+6 mU-min-ml™ after 10 mg/kg b.w. and of -10+10 mU-min-m!” after 30 mg/kg b.w. of Val-Pro-Leu (NS).
With reference to Figure 4, 100 mg/kg b.w. declined plasma DP IV activity at 5 min (10.4+3.2 mU/ml; p<0.05 vs. 0 min) after intravasal administration and DP IV-AUCo-20 min Was therefore slightly declined (-54+54 mU-min-mi™; NS).
The inhibition of plasma DP IV was always stopped 20 min after the administration.
’
Eglbmilrs EolaagEe EolzhdEa cqBe Ee ERS RBBE 0 sq@eCEd =] iii col Tf ov v El
E50 ob B= of Rt EY
E oT om Ot oy E ole © UO < E oC NEw = Ri= « oft = Rio © olf: « = low orld o SEI RIG 8 oSIBR oS REE
Do hl Hi 20 A A SST ET < : EE << va fi < URL FEE 3 gle © nis oy gla mio glo nu mloin 4 2 Ble & Sf = Ele wl v Segalma 3 ii i hil o Hi it ii ~ £ fi £ i £ i 5 low wf2 2 5 Zo w w(2 2 5 Zo 0 wS 2 = o E Hs) o E ig. 0 o E R=) > ES i EE i E& fi [ SH = iid [= di
Ye SHH iii EIEN < Ele Nit g 0 glee ni®ao® El eo mlEion =,
Ele ob ots = R=] PON Ela sli o
AS) = OER] SAN ERE SENT Ele Folio © = HE = pi = i
Oo He fie Hi = Hi i Hi
Q fh Feet EH
Q Qie Nat © 0 QIN © afi = olor © wfc «ol © Nir ob eS 0 oN Ni 1 [2:0 Nie o 0io:m 0) — TIN Ne OE oN “lo N=: NN TIN ON eee NN 0 ol wm nlsoo Rr HR als satin m
S eXgeE~Y SREY SER ERY £ ofr eliiv< olta mln olz wwii . <0 Sf NF RE] EEN © oF FIT 10 = TIN a Nfes DN Ml GIG] rN SRI: £ oli ela ole <lg-o oh eldioan
Soto oN © WE oO o oN Sais o SINR NSKIRE?R NEN elm © di iii A gd [A hag o SH o [HEH Ola oo ois So -— bs — Be ~~ ive w ii: fie Hiv @ RE Sal a o% wjoion olen
I I< o [oF wn H w [3 oH ° < QIKPN "KR gez@g~t veo z 5 ® owl =o a= <lo-o mnalsieo ola © QE Ow Olg of Ww | 0 Wo = |G oy RIK RK SR2[®OR bi vi {RA he Ht i fe = ole esis ao oleae nlgeo ore alton
No GN WG Fg NID 00 © oo Joie g NRSC R IEEE CE MERTEN => Wolenmfiong UWosanfgno Yokasibino py Zoe ont = Ola 8 SlFN 10 = Ojo © wisn ¥ a. = "NNN oN = female = |r Nem oN . TR BH RI HEH
Q 5 plzgs 22 T § 2288 0 5 & <<< ols < <<< . © Mek c wa bi ca c x £2 §9§ = §8§ |. F 558 a. geen E 2" 0 SE 2" 2 ok = 2 2S = = S55 = = EE = =
OE 5 UE t &E © =e Fo} fai d < g NN wo 3 i) EE2loan| EB E2aosl EB OEZTvgl OE o Wolo nd 5 Rolo oo 8 Bolooo 8 y-] mao 7 Shaw wow 0 FEO ww 0
The compounds lle-Pro-lle and Vai-Pro-Leu inhibit plasma DP IV-activity in Wistar ’ rats after intravasal administration in relatively high doses (100 mg/kg b.w.). With lle-
Pro-lle it seems to be a dose dependent inhibition of DP IV after intravasal administration.
THE INFLUENCE OF t-BUTYL-GLY-PRO-ILE ON PLASMA DP IV ACTIVITY IN WISTAR-RATS 100 mg/kg b.w. t-butyl-Gly-Pro-lle was administered oral and intravasal. With reference to figure 5, t-butyl-Gly-Pro-lle did decrease plasma DP IV slowly over a time period of 40 min when given orally. 100 mg/kg b.w. given intravasal, induced a very rapid decline below 10 mU/ml at 5 min (p<0.05). Thereafter a restoration (p<0.05 omin vs.40 min) was found. DP [V-AUCo.120 mn Was more declined after intra-vasal (- 6174234 mU-min-ml™) than after oral administration (-336+162 mU-min-mi™; p<0.05 vs. intra-vasal).
L
35 PCT/EP02/07128 21g Q eis § TERR Bi o| nN ~~ NY < +The
NER o © a 1 0 — [e) Die: O cla Kia 3 © Oo] K wm hws MN y . TEE © w alow © oh = ((o] Ste EET ¢ ors vx EF Is IN ye © 0 why on g 5S 3 El NP © oO N 10 hee ™ © LY. © 10 © = NY} NAN NG 2 ~~ 3 SiS © oo Si ) £ e &&8 YR s ol = mw = z
AT: IHL = NR ew? = DN ~~ Pog - = ol ~~ ®| © mr NN o OI N obs oN 0) O & oF te 10 = SII -— = wv Ql Kn TO . oN co IESE oy - Q, Ne hid
Q NEE oO 12 ! «-— © 10 fa o = a hl 2 ol ® ©| Mi < © ol & 88% 0) AS Se 2%
Pa N 0 > He eo © 1 «= 10 SRS C<t o EPR ad ~ ~ Of v= Es < 0) Q 2 = oC 2 0 Bh © < ® o oin py 3 o| J Si 93 > wo Nol Q <Q N © | OLE © ©
IS) =| or © chan ® © “4 - 5 0 3
Q oN el NN © Yn TRE ~ 1 TEN o ~ oN ORS “~— 0 0 wise oN nl <i © eh ~~
Yn ol, © Eo © < ~ Ty EE 0 ©
Oo - ) REE <3 ro) —| << | a ) © =| = [Te] ~E 3 3 - = - Rag NXT += nO fakin: 0 — es FEE oO © - N i QO RO] ~ 2
No = % FERRE 1D oO = oO FREE AS +3 Ne of oh oo MN K — ON via aM 2 EEE] RNS TaN en £ © © =i — © 3 wT 8 8 IQ e wn © — Open A od © NI Ny ohas ~ NN 3 pce: — NN BhE oh © oN - Re] on W] wo RR -— — - Py - 2] ol 2 © QE 13 ® 0 © QE 0 © g oe 1 oN . ~ na oo O Oo Rue RT) [o] [=] a - RN - - ® « NN -— Re iH “ ~N oN Ral © -s ww SE - 0} <T © SE ~~ RN nf ™ © EE 0 ® = ~ «= ED oO ~ - ) | © aEl — oo o 1S © hes pI b ON} WO I~ << NE w
SS © NEE om © 0) - LED NWO > eo NEE oO = Nee = Lo oN a oa © ES o =| Na Am = © © oho IN ~ = ohe no = © Sn @ > of Kj a ©0
B wo ~N ole 0 = a 9 ~ UE ) © ® © NE ER > 2 3 ts © 8 Lu SEs es © ol 8 88 HoH
Oo s Qe nN oo J | © Rl Cite 0 a. O| « EER 5 M > — 0] Oh NN
Eg £90 og = L&E YE
Q [ERT T RIT, oN N NR on oN Lu oO ~ cs an S29 & =23 Fg TL 38
S & 52 & Q SST Fa 26 = Po RE o I hhn ©
[1] mean = g pes a SRE At r 2 = = 5 2 E oc a E 9 T GE 5 90 bl 0 RRR = O ~~ i o 5 RaReac] [}] = 2 5 wm E o E = a 3 3 © Ea a =e DD 0
Ts mm = TN © © ahaa = cs 22 a NY a o iE > ©
Ef wo 38 88 » 2 2 = ~ 2 ie
RH nn 0 Ww oS a o J RY &
EE 0 wo 38 a
Table 8 shows the results of selected Xaa-Pro-Yaa tripeptides, tested for their . inhibitory potential of DPIV and DPIV-like enzyme activity after oral and intravasal administration to Wistar rats.
Table 8 Results — DPIV inhibiton at tax after administration of Xaa-Pro-Yaa fripeptides to Wistar rats
Structure Dose iv. (%) p.o. (%) (mg/kg)
EPs
EXAMPLE 4
The effect of Xaa-Pro-Yaa Tripeptides on glucose tolerance in diabetic Zucker rats
Study Design
ANIMALS
N=30 male Zucker rats (faffa), mean age 11 weeks (5-12 weeks), mean body weight } 350 g (150-400 g), were purchased from Charles River (Sulzfeld, Germany). They were kept for >12 weeks until all the fatty Zucker rats had the characteristics of manifest Diabetes mellitus.
HOUSING CONDITIONS
Animals were kept single-housed under conventional conditions with controlled temperature (2242 °C) on a 12/12 hours light/dark cycle (light on at 06:00 a.m.).
Standard pellets (ssniff®, Soest, Germany) and tap water acidified with HCI were allowed ad libitum.
CATHETERIZATION OF CAROTID ARTERY
Fatty Zucker rats, 17-24 weeks old, adapted to the housing conditions, were well prepared for the tests. Catheters were implanted into the carotid artery of fatty Zucker rats under general anaesthesia (i.p. injection of 0.25 mikg b.w. Rompun® [2 %],
BayerVital, Germany and 0.5 mlkg b.w. Ketamin 10, Atarost GmbH & Co.
Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 1U/ml) three times per week.
In case of catheter dysfunction, a second catheter was inserted into the contra-lateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 7 days after catheter implantation.
EXPERIMENTAL DESIGN
Fatty Zucker rats with intact catheter function were given in random order placebo (1 ml saline, 0.154 mol/l; N=9 animals as control), one uniform dose of isoleucyl thiazolidine*fumarate (10 mg/kg b.w. solved in 1 ml saline; N=6 animals) as positive control or 100 mg/kg b.w. test substance, solved in 1 ml saline (N=6 animals in each test group).
After overnight fasting, the fatty Zucker rats were given placebo, positive control and test substance, respectively, via feeding tube orally (15 G, 75 mm; Fine Science . Tools, Heidelberg, Germany) at ~10 min. An oral glucose tolerance test (OGTT) with 2 g/kg b.w. glucose as a 40 % solution (B. Braun Melsungen, Melsungen, Germany) was implemented at +0 min. The glucose was administered via a second feeding tube. Arterial blood samples from the carotid catheter were collected at ~30 min, -15 min, +0 min and at 5, 10, 15, 20, 30, 40, 60, 90 and 120 min into 20 pl glass : capillaries, which were placed in standard tubes filled with 1 ml solution for hemolysis (blood glucose measurement).
In addition, arterial blood samples were taken at ~30 min, at 20, 40 60 and 120 min from the carotid catheter of the conscious unrestrained fatty Zucker rats and given into ice cooled Eppendorf tubes (Eppendorf-Netheler-Hinz, Hamburg, Germany) filled with 10 yl sodium citrate buffer (pH 3.0) for plasma DP activity measurement.
Eppendorf tubes were centrifuged immediately (12000 rpm for 2 min, Hettich
Zentrifuge EBA 12, Tuttlingen; Germany): The plasma fractions were stored on ice until analysis.
ANALYTICAL METHODS
Blood glucose: Glucose levels were measured using the glucose oxidase procedure (Super G GlukosemeRgerat; Dr. Muller Geratebau, Freital, Germany).
Several tripeptides, tested in the in vivo assay according to example 4, improved significantly the glucose tolerance after oral administration during an OGTT in Zucker rats (see table 9 and figures 7 and 8).
Table 9 Results — Improvement of glucose tolerance after administration of Xaa-
Pro-Yaa tripeptides during an OGTT in Zucker rats
Compound Dose [Route |AUC Control |AUC test Improveme (mg/kg |of adm. |(mmol*min/l) {compound nt b.w.) (mmol*min/i) %
I a LE I I
VaPTIGy | 00 | pa | Bes | 7a | 1s
SO cc LC CO LL
EXAMPLE 5
Interaction of peptidic compounds with mammalian peptide transporters
For the analysis o the interaction of the inhibitors of prolyl-specific proteases with the mammalian peptide transporters two assay systems were used. First, all test compounds were submitted to the competition assay with transgenic yeast cells to determine the dose-dependent displacement (ECs, values) of the radiolabeled tracer dipepitde from the substrate binding site. Compounds identified as possessing good affinities were then submitted to electrophysiological analysis of transport currents in
Xenopus oocytes expressing the mammalian peptide transporters. As the level of functional expression varies in oocytes, each test compound was compared in the same oocyte with the current elicited by 5 mM of the dipeptide glycyl-L-glutamine (Gly-Gin). Currents of test compounds are therefore given relative to that by Gly-GIn as %l ay-cin, expressed as residual uptake in table 10.
Table 10 Results - interaction of peptidic compounds with mammalian peptide transporters
PEPT1 PEPT1 PEPT2 PEPT2
ECso (mM) Residual ECso (mM) Residual uptake uptake %lGly-Gin %lciy-cin
CrePote |oTEnae | w |omsoor 0 [Prete asmmE | 0 fowosoor] ©
SErete | ATES | 0 | aseim | 0 [PeiOyPoDVer | Wize | 0 | vesear | ©
Sy Pete | T0BE0M | 0 | sexie | 0
While the foregoing specifications teaches the principles of the present invention, with ’ examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications envisioned by one of ordinary skill in the art.

Claims (1)

  1. cE . Da WO 03/002503 PCT/EP02/07128 CLAIMS
    CL. 1. A compound represented by the general formula (1): Pa Pa : A c E (I) and pharmaceutically acceptable salts thereof, wherein A is any amino acid except a D-amino acid; ~~ Bis an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine~(2)-carboxylic acid and pipecaolic acid, C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, D is any amino acid or missing, and E is any amino acid or missing; or : : wherein C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, and excepta : D-amino acid, D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids. AMENDED SHEET 2004 -05- 19 g WO 03/002593 PCT/EP02/07128 co 2. The compound of claim 1, wherein :
    Co. Als any amino acid except a D-amino acid; B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine~(2)-carboxylic acid and pipecolic acid, C is any amino acid except Pro, Hyp, acetidine~(2)-carboxylic acid, pipecalic acid and except N-alkylated amino acids, D is any amino acid or missing, and E is any amino acid or missing. oo
    + 3. The compound of claim 1, wherein A is any amino acid except a D-amino acid; B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic - acid and pipecolic acid, C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids . and except a D-amino acid, D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and E is any amino acid except Pro, Hyp, acetidine~(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids.
    4. The compound of any one of the preceding claims, wherein Ais a L-amino acid.
    5. The compound of any one of the preceding claims, wherein C is a L-amino acid. AMENDED SHEET 2004 -05- 19
    ‘ 6. The compound of any one of the preceding claims, wherein E is missing.
    7. The compound of any one of the preceding claims, wherein D and E are missing.
    8. The compound of any one of the preceding claims, wherein A is t-butyl-Gly, lie or Val.
    9. The compound of any one of the preceding claims, wherein B is Pro.
    10. The compound of any one of the preceding claims, wherein C is t-butyl-Gly, lle or Val.
    11. The compound of any one of the preceding claims, wherein D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid.
    12. The compound of claim 1, namely t-butyl-Gly-Pro-lle; t-butyl-Gly-Pro-Val; Val- Pro- t-butyl-Gly, lle-Pro-t-butyl-Gly or t-butyl-Gly-Pro-t-butyl-Gly and pharmaceuticaly acceptable salts thereof.
    13. The compound of any one of the preceding claims, wherein the compound is the free acid peptide form or the C-terminal amide peptide form.
    - ? a.
    14. The compound of claim 13, wherein the free acid peptide form or the C-terminal ‘ amide peptide form is varied by side chain modifications selected from homoserine addition, pyroglutamic acid addition, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t-butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, benzyloxymethylation, 4- nitrophenylation, benzyloxycarbonylation, 2-nitrobenzoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2- chlorobenzyloxycarbonylation, 2,4,5-trichlorophenylation, 2-bromobenzyloxycarbonyl- ation, 9-fluorenylmethyloxycarbonylation, triphenylmethylation, 2,2,5,7,8,-penta- methylchroman-6-sulphonylation, hydroxylation, oxidation of methionine, formylation, acetylation, anisylation, benzylation, benzoylation, trifluoroacetylation, carboxylation of aspartic acid or glutamic acid, phosphorylation, sulphation, cysteinylation, glycolysation with pentoses, deoxyhexoses, hexosamines, hexoses or N- acetylhexosamines, farnesylation, myristolysation, biotinylation, palmitoylation, stearoylation, geranylgeranylation, glutathionylation, 5-adenosylation, ADP- ribosylation, modification with N-glycolylneuraminic acid, N-acetylneuraminic acid, pyridoxal phosphate, lipoic acid, 4’ -phosphopantetheine, and N-hydroxysuccinimide.
    15. Prodrugs of a compound of any one of the preceding claims.
    16. A pharmaceutical composition comprising at least one compound or prodrug of any one of claims 1 to 15 and a pharmaceutically acceptable carrier and/or diluent.
    17. A process for making a pharmaceutical composition comprising mixing at least one compound or a prodrug of any one of claims 1 to 15 and a pharmaceutically acceptable carrier and/or diluent.
    18. Use of a compound, a prodrug or a composition according to any one of the
    . preceding claims 1 to 15 for the preparation of a medicament for the prophylaxis or treatment of a condition mediated by modulation of the dipeptidyl peptidase IV activity.
    . 18. Use of claim 17, wherein the condition is selected from impaired glucose . tolerance, diabetes mellitus, glucosuria and metabolic acidosis. ) 20. A compound according to claim 1, other than the compound of claim 15, as specifically - described herein.
    AMENDED SHEET 2004 -05- 1 g
ZA200301312A 2001-06-27 2002-06-27 Peptide structures useful for competitive modulation of dipertidyl peptidase IV catalysis. ZA200301312B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01114796 2001-06-27

Publications (1)

Publication Number Publication Date
ZA200301312B true ZA200301312B (en) 2004-03-30

Family

ID=8177756

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200301312A ZA200301312B (en) 2001-06-27 2002-06-27 Peptide structures useful for competitive modulation of dipertidyl peptidase IV catalysis.
ZA200300833A ZA200300833B (en) 2001-06-27 2002-06-27 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents.
ZA200300595A ZA200300595B (en) 2001-06-27 2003-01-22 Use of dipeptidyl peptidase IV inhibitors.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA200300833A ZA200300833B (en) 2001-06-27 2002-06-27 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents.
ZA200300595A ZA200300595B (en) 2001-06-27 2003-01-22 Use of dipeptidyl peptidase IV inhibitors.

Country Status (8)

Country Link
EP (1) EP1399469A2 (en)
JP (1) JP2004530729A (en)
CN (2) CN1471538A (en)
CA (1) CA2419888A1 (en)
NO (1) NO20030900L (en)
RU (2) RU2299066C2 (en)
WO (1) WO2003002593A2 (en)
ZA (3) ZA200301312B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10211555A1 (en) * 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Use of the inhibitors of enzymes with activities of the aminopeptidase N and / or the dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of dermatological diseases with sebocytic hyperproliferation and changed differentiation states
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
KR20120035203A (en) 2003-05-05 2012-04-13 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
PL1620082T3 (en) 2003-05-05 2010-10-29 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ546322A (en) 2003-10-15 2008-11-28 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR20170005163A (en) 2003-11-17 2017-01-11 노파르티스 아게 Use of dipeptidyl peptidase iv inhibitors
ES2332920T3 (en) 2004-01-20 2010-02-15 Novartis Ag PROCESS AND FORMULATION OF DIRECT COMPRESSION.
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
JP2008501714A (en) 2004-06-04 2008-01-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2574418A1 (en) 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
DE602005022089D1 (en) 2004-08-06 2010-08-12 Merck Sharp & Dohme SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DK1831361T3 (en) * 2004-12-23 2012-05-14 Campina Nederland Holding Bv Protein hydrolyzate enriched with peptides that inhibit DPP-IV and their use
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
ES2574014T3 (en) 2005-05-30 2016-06-14 Msd K.K. Novel Piperidine Derivative
JP2011201923A (en) * 2005-07-01 2011-10-13 Snow Brand Milk Products Co Ltd Dipeptidyl peptidase iv inhibitor
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
RU2008116844A (en) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Acylated Spiropiperidine Derivatives as Modulators of the Melanocortin-4 Receptor
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
WO2007054577A1 (en) 2005-11-14 2007-05-18 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
JP2009517464A (en) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． Use of protein hydrolysates that enhance the activity of glucagon-like peptide 1
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
NZ571761A (en) 2006-04-12 2010-07-30 Probiodrug Ag 5-phenylimidazoles
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8338458B2 (en) 2007-05-07 2012-12-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
CA2731358A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CN102264228A (en) 2008-10-22 2011-11-30 默沙东公司 Novel cyclic benzimidazole derivatives useful for anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (en) 2008-10-31 2011-12-07 默沙东公司 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009314200B2 (en) 2008-11-17 2011-11-17 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
MX2012011631A (en) 2010-04-06 2013-01-18 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN103476258B (en) 2011-02-25 2017-04-26 默沙东公司 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2681236B1 (en) 2011-03-01 2018-01-03 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
CN103987724A (en) * 2011-11-04 2014-08-13 株式会社日皮 Dpp-4 inhibitor
US9617300B2 (en) * 2012-03-09 2017-04-11 Morinaga Milk Industry Co., Ltd. Dipeptidyl peptidase-IV inhibitor
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
SG11201602161XA (en) 2013-09-23 2016-04-28 Wolff August Gmbh & Co Kg Arzneimittel Dr Anti-inflammatory tripeptides
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2901114T3 (en) 2014-08-29 2022-03-21 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN105362272A (en) * 2015-12-14 2016-03-02 上海壹志医药科技有限公司 Pharmaceutical application of rotundine
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN110551203B (en) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 Exenatide analogue
BR112023002957A2 (en) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR TREATING NARCOLEPSY AND FOR TREATING HYPERSONIA IN A MAMMAL SUBJECT

Also Published As

Publication number Publication date
ZA200300595B (en) 2004-02-13
JP2004530729A (en) 2004-10-07
RU2003105463A (en) 2004-11-27
WO2003002593A3 (en) 2003-09-04
NO20030900L (en) 2003-04-24
NO20030900D0 (en) 2003-02-26
EP1399469A2 (en) 2004-03-24
RU2299066C2 (en) 2007-05-20
WO2003002593A2 (en) 2003-01-09
CA2419888A1 (en) 2003-01-09
ZA200300833B (en) 2004-02-10
CN1471538A (en) 2004-01-28
CN1688599A (en) 2005-10-26

Similar Documents

Publication Publication Date Title
ZA200301312B (en) Peptide structures useful for competitive modulation of dipertidyl peptidase IV catalysis.
US20030135023A1 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
RU2305553C2 (en) New dipeptidyl peptidase iv inhibitors and uses thereof as hypotensive agent
US6946480B2 (en) Glutaminyl based DPIV inhibitors
US20050107308A1 (en) Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
AU2002328306B2 (en) Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders
EP1434792B1 (en) Peptidyl ketones as inhibitors of dpiv
AU2002328306A1 (en) Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders
US20030125304A1 (en) Substituted amino ketone compounds
JP2005514336A5 (en)
DD297169A5 (en) PEPTIDES WITH BRADYKININ ANTAGONISTIC EFFECT
EP3453711B1 (en) Llp2a- bisphosphonate conjugates for osteoporosis treatment
AU2002328305A1 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
CENTER Pospisilik et al.(43) Pub. Date: Sep. 18, 2003
US20060194852A1 (en) Glutaminyl based DPIV inhibitors
NZ545366A (en) Glutaminyl based DPIV inhibitors